.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Healthtrust
Harvard Business School
Merck
Farmers Insurance
Boehringer Ingelheim
Citi
Cantor Fitzgerald
Colorcon
UBS

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,727,552

« Back to Dashboard

Summary for Patent: 7,727,552

Title:Oral pharmaceutical preparations decreased in bitterness by masking
Abstract:A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
Inventor(s): Ukai; Koji (Gifu, JP), Hrada; Tsutomu (Aichi, JP), Suzuki; Yasuyuki (Gifu, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:09/380,310
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

No matches for this query

Foreign Priority and PCT Information for Patent: 7,727,552

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-078568Mar 28, 1997
Japan9-343265Dec 12, 1997
PCT Information
PCT FiledMarch 26, 1998PCT Application Number:PCT/JP98/01360
PCT Publication Date:October 08, 1998PCT Publication Number: WO98/43675

International Patent Family for Patent: 7,727,552

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4234666► Subscribe
Japan2005041887► Subscribe
Japan3770518► Subscribe
JapanH11228450► Subscribe
Spain2273409► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Covington
McKesson
US Department of Justice
Teva
Federal Trade Commission
US Army
Novartis
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot